Sotorasib

  • TRADE NAMES: AMG 510; Lumakras (Amgen)
  • INDICATIONS:

    Advanced or metastatic non-small cell lung cancer in patients with the KRAS p.G12C-mutation.

    This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 


  • CLASS: Ras–GTPase inhibitor
  • HALF-LIFE: 5 hours

FDA APPROVAL DATE: 05/28/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

CYP3A4 inducers, CYP3A4 substrates, Digoxin, Famotidine, H2 receptor antagonists, Itraconazole, Metformin, Omeprazole, P-gp substrates, Proton pump inhibitors, Rifampin


No available data for use in pregnant women.

Our database has 33 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.


Page last updated 09/18/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top